Prograf outperforms other anti-rejection drugs in study

12/20/2007 | Yahoo!

Researchers found small doses of Astellas Pharma's Prograf more effective than other drugs in preventing the immune system from rejecting transplanted kidneys. Patients who got low-dose Prograf recorded a short-term rejection rate of 12%, while recipients of Wyeth's low-dose Rapamune showed a rejection rate of 37%.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC